Comparative Benchmarking
In the context of the broader market, RGC competes directly with industry leaders such as IONS and MDGL. With a market capitalization of $13.46B, it holds a significant position in the sector. When comparing efficiency, RGC's gross margin of N/A stands against IONS's 98.51% and MDGL's 93.69%. Such benchmarking helps identify whether Regencell Bioscience Holdings Ltd is trading at a premium or discount relative to its financial performance.
